Article
BRAFV600E mutation status of involuting and stable nevi in dabrafenib therapy with or without trametinib.
JAMA dermatology - 1 Oct 2014
McClenahan Phil, Lin Lynlee L, Tan Jean-Marie, Flewell-Smith Ross, Schaider Helmut, Jagirdar Kasturee, Atkinson Victoria, Lambie Duncan, Prow Tarl W, Sturm Richard A, Soyer H Peter
Abstract excerpt
IMPORTANCE: Recent advances in targeting BRAFV600E mutations, which occur in roughly 50% of melanomas and 70% of benign nevi, have improved response rates and survival in patients with melanoma. With increased survival, the importance of other comorbidities increases and requires consideration in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.